{{Rsnum
|rsid=5030655
|Gene=CYP2D6
|Chromosome=22
|position=42525086
|Orientation=plus
|ReferenceAllele=T
|GMAF=0.0101
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(-;-)
|geno2=(-;T)
|geno3=(T;T)
}}The (-) form of this SNP, representing a deletion of one nucleotide, causes a frameshift such that the resulting [[CYP2D6]] protein is nonfunctional. The associated allele is also known as CYP2D6*6, and there are several subtypes but they are all nonfunctional.

If two copies of this (or similar) changes are inherited, CYP2D6 poor metabolism ('PM') is observed. 

[[CYP2D6]] poor metabolism may affect the efficacy or degree of side effects of drugs metabolized by CYP2D6, such as [[dextromorphan]], [[sparteine]], [[nortriptyline]], [[venlafaxine]] and [[codeine]].
{{ neighbor
| rsid = 3892097
| distance = 139
}}

{{PharmGKB
|RSID=rs5030655
|Name_s=CYP2D6:1707 del T, part of CYP2D6*6
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19037197; Web Resource:http://preview.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp
|Annotation=This variant is part of the CYP2D6*6 PM haplotype. Plasma concentrations of metoprolol were shown to be were 4.9-fold higher in the PMs, with greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs.
|Drugs=metoprolol
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162372818
}}

{{PharmGKB
|RSID=rs5030655
|Name_s=CYP2D6*6; CYP2D6:1707 del T
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp#ImportantVariantInformationforCYP2D6-444
|Annotation=Causes a frameshift mutation that results in a truncated, non-functional version of CYP2D6 and is diagnostic for the haplotype CYP2D6*6.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145188
}}

{{PharmGKB
|RSID=rs5030655
|Name_s=CYP2D6:1707 del T; CYP2D6*6
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=PubMed ID:16958828
|Annotation=This variant is the defining SNP for CYP2D6*6 and encodes a non-functional variant of CYP2D6. Individuals with CYP2D6 *6/*4 , *5/*4 or *6/*6 genotypes are poor metabolizers of venlafaxine and are more prone to drug-induced side effects such as nausea, vomiting and diarrhea. However, CYP2D6 genotype does not seem to influence venlafaxine efficacy.
|Drugs=venlafaxine
|Drug Classes=
|Diseases=Depression; Depressive Disorder; Depressive Disorder, Major; Diarrhea; Drug Toxicity; Nausea; Vomiting
|Curation Level=Curated
|PharmGKB Accession ID=PA162316613
}}

{{PMID|20174590|OA=1
}} Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

{{GET Evidence
|gene=CYP2D6
|aa_change=Trp152Shift
|aa_change_short=W152Shift
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5030655
|overall_frequency_n=1
|overall_frequency_d=128
|overall_frequency=0.0078125
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=0
|n_articles_annotated=0
|nblosum100=4
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}